TAP Biosystems has installed a 48-bioreactor version of its micro bioreactor system at a European pharmaceutical company to improve the productivity of cell line development for antibody therapeutics.
The system will assist in predicting how antibody-expressing cell lines will behave in large-scale bioreactors.
The advanced micro bioreactor system (AMBR), which closely replicates the characteristics of bioreactors at micro scale (10-15ml working volume), was selected by the company following an onsite evaluation of AMBR using its antibody-expressing CHO cell lines.
The system was chosen after the pharmaceutical company's process development scientists demonstrated the scalability of culture performance between AMBR-, laboratory- and manufacturing-scale bioreactors.
The AMBR 48 system can investigate the effects of 48 different combinations of cell line and culture conditions.
The system also enables testing of up to four different temperature and stirrer speeds in one real-time run, with less operator time than would be required to perform similar experiments in lab-scale bioreactors.
The company now plans to use AMBR to help select the best antibody clones for use in production runs.
